

Stereoselective ring-opening reactions with AcBr and AcCl. A new method for preparation of some haloconduritol

Arif Baran, Cavit Kazaz and Hasan Seçen*

Department of Chemistry, Faculty of Arts and Sciences, Ataturk University, 25240 Erzurum, Turkey

Received 16 August 2003; revised 28 October 2003; accepted 20 November 2003

Abstract—The actions of AcX (X=Br, Cl) on 7-oxa-bicyclo[2.2.1]hept-5-ene-2,3-diol diacetates and a *transoid*-epoxide prepared from the acetone of cyclohexa-3,5-diene-*cis*-1,2-diol were studied. H₂SO₄-catalyzed cleavage of *exo-cis*-7-oxa-bicyclo[2.2.1]hept-5-ene-2,3-diol diacetate with AcCl gave (1 α ,2 α ,3 α ,6 β)-6-chloro-4-cyclohexene-1,2,3-triol triacetate, from which the corresponding chloroconduritol was obtained by *trans*-esterification (MeOH/HCl). A similar reaction of the *exo*-diacetate with AcBr in the presence of H₂SO₄ resulted in bromine addition. The formation of bromine from the reaction of AcBr and H₂SO₄ was observed by independent experiments. H₂SO₄-catalyzed reaction of *endo-cis*-7-oxa-bicyclo[2.2.1]hept-5-ene-2,3-diol diacetate with AcX (X=Br, Cl) gave (1 α ,2 α ,3 β ,6 β)-6-halo-4-cyclohexene-1,2,3-triol triacetates. The reaction of the *transoid*-epoxide with AcX (X=Br, Cl) with no catalyst gave also (1 α ,2 α ,3 β ,6 β)-6-halo-4-cyclohexene-1,2,3-triol triacetates.

© 2003 Elsevier Ltd. All rights reserved.

1. Introduction

Glycosidase inhibitors have become interesting as anti-obesity drugs, antidiabetics, antifungals, insecticides, and antivirals, including substances active against the human immunodeficiency virus (HIV) and metastasis.¹ Bromoconduritol, a diastereomeric mixture of (1 α ,2 β ,3 α ,6 β)-6-bromo-4-cyclohexene-1,2,3-triol and (1 α ,2 β ,3 α ,6 α)-6-bromo-4-cyclohexene-1,2,3-triol, has been commonly used as a covalent, irreversible, active-site directed glucosidase inhibitor.²

A few synthetic procedures^{2d,3} for the preparation of haloconduritol have been described. Recently, we have reported⁴ a facile synthesis of haloconduritol based on Lewis acid (BBr₃ or BCl₃)-assisted ring-opening of *endo*-diacetate **1** at low temperature. Thus, our method gives haloconduritol diacetates **2a**, **3a** in the construction of conduritol-A, from which haloconduritol **2c**, **3c** were efficiently prepared (Scheme 1).

Mechanistic investigations have revealed that ring-opening of *endo*-diacetate **1** proceeds by a neighboring group participation. A neighboring group participation is not expected in *exo*-diacetate **4** due to the relative stereochemistry. Ring-opening of *exo*-diacetate **4** should afford a

different haloconduritol. Thus, we planned to investigate the ring-opening of *exo*-diacetate **4**. Also, considering high reactivity of epoxides to give halohydrins, we studied the ring-opening reactions of epoxide **5** to give haloconduritol (Fig. 1).

2. Results and discussion


At first, we attempted the BX₃-assisted ring-opening of *exo*-diacetate **4**. We treated *exo*-diacetate **4** with BBr₃ or BCl₃ at –78 °C and then, the reaction mixture was stirred at room temperature for 4 h. After quenching the reaction with water and chromatographic separation, we determined that the reaction with BBr₃ gave three products (**6**, **7**, and **8**). Attempts to ring-open **4** with BCl₃ were unsuccessful (Scheme 2).

The formation of **6–8** may be explained via haloborane. Haloborane of olefins with BBr₃ has been known⁵ for a long time. Formation of monobromide **6** and **7** may be easily explained by addition of BBr₃ to the double bond of **4** to give Br–C–C–BBr₂-like intermediates **9** and **10** followed by hydrolysis. The formation of **8** probably proceeds through the oxidation of C–B bond of intermediate **10** by air oxygen to give **11** (Scheme 3). Indeed, performing the reaction under N₂ atmosphere and quenching the reaction media with water gave only dibromides **6** and **7** in a ratio of 1:1 and total yield of 65%.

Cleavage of ethers by acyl halides have been known for over

Keywords: Haloconduritol; Ring-opening; 7-Oxa-bicyclo[2.2.1]hept-5-ene-2,3-diol diacetate; Cyclohexa-3,5-diene-*cis*-1,2-diol; Acetyl bromide; Acetyl chloride.

* Corresponding author. Tel.: +90-442-2314409; fax: +90-442-2360948; e-mail address: hsecen@atauni.edu.tr



Scheme 1. (i) BX_3 , CH_2Cl_2 , -78°C , then H_2O ($\text{BX}_3=\text{BBr}_3$ or BCl_3) (ii) CH_3COCl , CH_2Cl_2 ; (iii) MeOH , HCl , 0°C .

50 years.⁶ Considering the efficiency of the reaction to give alkyl halides and alcohols we applied this method to *exo*-diacetate **4**. For this, we treated *exo*-diacetate **4** with excess AcCl in the presence of H_2SO_4 . As expected, the reaction gave chloroconduiritol triacetate **13a** in the construction of conduiritol-C, from which chloroconduiritol **13b** was readily obtained by *trans*-esterification. The ^1H NMR spectra of **13a,b** showed an identity with similar C-type haloconduiritol derivatives.^{3c,7} As a surprising result, the reaction of *exo*-diacetate **4** with AcBr and H_2SO_4 gave a brominated compound **12** (Scheme 4).

We assumed that brominated compound **12** should be formed via addition of Br_2 to the double bond of **4**. As evidence, one drop of Br_2 was added to a solution of *exo*-diacetate **4** in CDCl_3 in an NMR tube, and the NMR spectra showed the formation **12** as a sole product. To our knowledge, there has not been any report on the formation of bromine from the reaction of AcBr and H_2SO_4 . Therefore, the formation of bromine from AcBr and H_2SO_4 was provided by performing an independent experiment. To a stirred solution of 50 mmol AcBr in CH_2Cl_2 was added one drop H_2SO_4 and the reaction mixture was additionally stirred for 15 min. Meanwhile the colorless reaction mixture turned red. To determine the quantity of the bromine, 25 mmol cyclohexene was added and after purification only 0.8 mmol 1,2-dibromocyclohexane was obtained. In another experiment, after treatment of 50 mmol AcBr with 50 mmol H_2SO_4 in dichloromethane, 25 mmol cyclohexene was added to reaction mixture. This time, isolated 1,2-dibromocyclohexane was 22 mmol. These findings show that the decomposition of AcBr with H_2SO_4 is not a catalytic





Figure 1.


reaction. Most probably, H_2SO_4 seems to participate in the reaction as a reagent. At this stage we did not study the mechanism of the reaction.

Complete peak assignments of the NMR spectra of **6**, **7**, **8** and **12** were carried out. Taking into consideration the coupling constants, we easily elucidated the relative stereochemistry of H_2 , H_3 , H_5 and H_6 . In the ^1H NMR spectra of these four compounds $J_{1,2}$ and $J_{3,4}$ were not observed probably due to dihedral angles close to 90° . Similar results were reported in benzobicyclic[2.2.1]system having *exo*-substituents.⁸ Again, all $J_{2,3}$ values are about 6.2 Hz. $J_{5,6}$ of **8**, similar to $J_{2,3}$, is also 6.3 Hz. While *endo*- H_5 of **7** is seen as a doublet of doublets ($J_{5,6endo}=7.0$ Hz, $J_{5,6exo}=4.0$ Hz), *exo*- H_5 of **6** is seen as doublet of triplets ($J_{5,6exo}=10.9$ Hz, $J_{5,6endo}=5.0$ Hz, $J_{4,5}=5.0$ Hz). The configurations of the groups in **7** and **8** were also confirmed by the observation of NOE effects. In **7**, irradiation of $\text{H}-\text{C}_5(\text{Br})$ at δ 4.03 caused signal enhancement of the resonances at H_2 , H_3 and adjacent protons at C_6 . In a similar way, irradiation of $\text{H}-\text{C}_6(\text{OH})$ of **8** at δ 3.94 caused signal enhancement of the resonances at H_1 , H_2 , H_3 and H_5 .

In our previous studies, BBr_3 or BCl_3 -assisted ring-opening of *endo*-diacetate **1** required a temperature of -78°C .




Scheme 2. (i) BBr_3 , CH_2Cl_2 , -78°C , then H_2O (ii) BCl_3 , CH_2Cl_2 , -78°C , then H_2O .



Scheme 3. Possible mechanism for the formation 6–8 from 4.

Therefore we attempted to ring-opening of **1** with AcX (X=Br, Cl) at ambient temperature. The reaction gave haloconduritol triacetates **2b** and **3b** in good yields (Scheme 5). The reaction appears to proceed by neighboring group participation as with the reaction in Scheme 1.


Epoxide **5**, readily prepared by epoxidation of acetone **14**, is highly reactive to substitution and has been used for many




Scheme 4. (i) AcCl, CH₂Cl₂, H₂SO₄; (ii) MeOH, HCl; (iii) AcBr, CH₂Cl₂, H₂SO₄.

syntheses in the literature.⁹ Without any catalyst, the reaction of epoxide **5** with excess of acetyl halides (X=Br, Cl) gave directly **2b** and **3b** in good yields (Scheme 6).

We suppose that the formation of products **2b** and **3b** proceeds by an S_N2' mechanism as outlined in Scheme 7. At first, epoxide **5** and acetyl halide should give a **15**-like tetrahedral intermediate. While halide is being transferred to the 6-position, the electron pair of the double bond could substitute carbon–oxygen bond of epoxide at C₄ to give **16**-like product. Further acetylation of ketal oxygens with acetyl halide affords haloconduritol triacetates **2b** and **3b**. Similar S_N2' substitutions were observed in the reactions of **5** or **5**-like unsaturated epoxides with some organometallic reagents.¹⁰



Scheme 5. (i) AcX (X=Br, Cl), CH₂Cl₂, H₂SO₄ (cat).



Scheme 6. (i) MCPBA, (ii) AcX (X=Br, Cl), CH₂Cl₂.


3. Conclusion

In conclusion, we describe in this paper a preparation method for a new chloroconduritol **13b** in the construction of conduritol-C. We also describe two new methods for the preparation of haloconduritol triacetates **2b** and **3b** from *endo*-diacetate **1** and epoxide **5** via cleavage with acetyl halides. Deacetylation of triacetates **2b** and **3b** by *trans*-esterification (MeOH/HCl) to give the corresponding haloconduritols was reported in our previous paper.⁴

4. Experimental

4.1. General information

Solvents were purified and dried by standard procedures before use. Melting points were determined on Büchi 539 capillary melting apparatus and uncorrected. Infrared spectra were obtained from KBr pellets or film on a Mattson 1000 FT-IR spectrophotometer. The ¹H and ¹³C NMR spectra were recorded on 200 (50) MHz Varian spectrometers. Elemental analyses were carried out on a Carlo Erba 1108 model CHNS-O analyser. Column chromatography was performed on silica gel 60 (70–230 mesh ASTM). Thin layer chromatography was carried out on Merck 0.2 mm silica gel, 60 F₂₅₄ analytical aluminum plates.



Scheme 7. Suggested mechanism for the formation of **2b** and **3b** from epoxide **5**.

4.1.1. *endo*-cis-7-Oxa-bicyclo[2.2.1]heptane-2,3-diol diacetate (1).⁴ **1** was prepared from *endo*-cycloadduct of furan and vinylene carbonate according to our previously reported procedure.⁴

4.1.2. *exo*-cis-7-Oxa-bicyclo[2.2.1]heptane-2,3-diol diacetate (4).⁴ **4** was prepared from *exo*-cycloadduct of furan and vinylene carbonate according to our previously reported procedure.⁴

4.1.3. *cis*-1,2-Isopropylidenedioxycyclohexa-3,5-diene (14). Acetonide **14** was prepared from 1,4-cyclohexadiene as described by Yang¹¹ et al. A direct preparation of **14** from cyclohexa-3,5-diene-*cis*-1,2-diol in a high yield is also described by Ramesh^{9b} et al.

4.1.4. (3α,5αβ,6αβ,6β)-2,2-dimethyl-3a,5a,6a,6b-tetrahydro-oxireno[*e*]-1,3-benzo-dioxole (5). Epoxide **5** was prepared by epoxidation of acetonide **14** with *m*-chloroperbenzoic acid following the reported procedure by Banwell^{9f} et al.

4.1.5. The reaction of *exo*-diacetate **4 with BBr₃.** *Method A.* Under nitrogen atmosphere, to a stirred solution of *exo*-diacetate **4** (1.00 g, 4.7 mmol) in 20 mL of CH₂Cl₂ was added dropwise a solution of BBr₃ (0.5 mL, 1.30 g, 5.2 mmol) in 20 mL of CH₂Cl₂ at –78 °C over 10 min. After addition was completed, the mixture was stirred at 0 °C for 1 h, and then at room temperature for 4 h under air atmosphere. To the reaction mixture was added 5 mL of saturated NaHCO₃ solution. The organic phase was separated. The aqueous phase was additionally extracted with CHCl₃ (3×30 mL). The combined organic phases were dried over Na₂SO₄. The solvent was evaporated (30 °C, 25 mm Hg) and the product was chromatographed on a silica gel column (70 g) eluting with hexane–EtOAc (3:1).

*The first fraction (2*exo*,3*exo*,5*endo*)-5-Bromo-7-oxa-bicyclo[2.2.1]heptan-2,3-diol diacetate (6).* (0.40 g, %28). Colorless crystal. Mp 125–127 °C (solidified). ¹H NMR (200 MHz, CDCl₃) δ 5.66 (d, 1H, H₃, J_{2,3}=6.2 Hz), 4.97 (d, 1H, H₂, J_{2,3}=6.2 Hz), 4.50 (d, 1H, H₄, J_{4,5}=5.0 Hz), 4.42 (d, 1H, H₁, J_{1,6*exo*}=6.2 Hz), 3.98 (dt, 1H, H₅, J_{5,6*exo*}=10.9 Hz, J_{5,6*endo*}=5.0 Hz, J_{4,5}=5.0 Hz), 2.53 (ddd, 1H, H₆ (*exo*), J_{6*endo*,6*exo*}=15.9 Hz, J_{5,6*exo*}=10.9 Hz, J_{1,6*exo*}=6.2 Hz), 1.65 (dd, 1H, H₆ (*endo*), J_{6*endo*,6*exo*}=15.9 Hz, J_{5,6*endo*}=5.0 Hz), 2.12 (s, 3H), 2.08 (s, 3H). ¹³C NMR (50 MHz, CDCl₃) δ 171.3 (2C), 83.9, 82.7, 77.4, 75.8, 41.6, 38.4, 22.4, 22.3. IR (KBr) 2993, 2923, 2854, 1747, 1438, 1388, 1245, 1130, 1064, 1041, 906 cm⁻¹. Anal. calcd for C₁₀H₁₃BrO₅ (293.11): C, 40.98; H, 4.47; Found: C, 40.61, H, 4.35.

Second fraction (2*exo*,3*exo*,5*exo*)-5-Bromo-7-oxa-bicyclo[2.2.1]heptan-2,3-diol diacetate (7). (0.30 g, %22). Colorless crystal. Mp 134–136 °C (solidified). ¹H NMR (200 MHz, CDCl₃) δ 4.87 (A part of AB system, d, 1H, H₂ or H₃, *J*_{2,3}=6.2 Hz), 4.80 (B part of AB system, d, 1H, H₂ or H₃, *J*_{2,3}=6.2 Hz), 4.60 (br d, 1H, H₁, *J*_{1,6*exo*}=5.0 Hz), 4.56 (br s, 1H, H₄), 4.03 (dd, 1H, H₅, *J*_{5,6*endo*}=7.0 Hz, *J*_{5,6*exo*}=4.0 Hz), 2.27–2.06 (AB system, m, 2H, H₆ (*endo*) and H₆ (*exo*)), 2.06 (s, 6H). ¹³C NMR (50 MHz, CDCl₃) δ 172.1, 171.8, 88.8, 81.8, 76.9, 75.3, 44.4, 40.5, 22.5, 22.4. IR (KBr) 3031, 3012, 1747, 1438, 1388, 1373, 1257, 1218, 1195, 1141, 1064, 1002, 944, 898 cm⁻¹. Anal. calcd for C₁₀H₁₃BrO₅ (293.11): C, 40.98; H, 4.47; Found: C, 40.51, H, 4.64.

Third fraction (2*exo*,3*exo*,5*exo*,6*exo*)-5-Bromo-7-oxa-bicyclo[2.2.1] heptan-2,3,6-triol 2,3-diacetate (8). (0.60 g, %41). Colorless crystal. Mp 149–151 °C (solidified). ¹H NMR (200 MHz, CDCl₃) δ 4.94 (A part of AB system, d, 1H, H₂ or H₃, *J*_{2,3}=6.2 Hz), 4.91 (B part of AB system, d, 1H, H₂ or H₃, *J*_{2,3}=6.2 Hz), 4.56 (br d, 1H, H₄, *J*_{1,4}=2.2 Hz), 4.41 (d, 1H, H₁, *J*_{1,4}=2.2 Hz), 4.27 (d, 1H, H₅, *J*_{5,6}=6.3 Hz), 3.94 (dd, 1H, H₆, *J*_{5,6}=6.3 Hz, *J*_{6,OH}=9.5 Hz), 2.35 (d, 1H, OH, *J*_{6,OH}=9.5 Hz), 2.10 (s, 3H), 2.09 (s, 3H). ¹³C NMR (50 MHz, CDCl₃) δ 171.5, 171.4, 89.0, 88.4, 74.8, 73.5, 72.1, 55.0, 22.3 (2C). IR (KBr) 3455, 3394, 1643, 1554, 1469, 1427, 1052, 1025, 964 cm⁻¹. Anal. calcd for C₁₀H₁₃BrO₆ (309.11): C, 38.86; H, 4.24; Found: C, 39.10, H, 4.31.

Method B. Under nitrogen atmosphere, to a stirred solution of *exo*-diacetate **4** (0.160 g, 0.75 mmol) in 20 mL of CH₂Cl₂ was added dropwise a solution of BBr₃ (0.1 mL, 0.26 g, 1.0 mmol) in 20 mL of CH₂Cl₂ at -78 °C over 10 min. After addition was completed, the mixture was stirred at 0 °C for 1 h, and then at room temperature for 4 h under nitrogen atmosphere. After quenching of the reaction mixture with water (1 mL), organic phase was separated, dried (Na₂SO₄). Removing of the solvents gave a mixture of monobromides **6** and **7** in a ratio of 1: 1 (according to ¹H NMR) (0.143 g; 65%).

4.1.6. (1 α ,2 α ,3 α ,6 β)-6-Chloro-4-cyclohexene-1,2,3-triol triacetate (13a). To a solution of *exo*-diacetate **4** (0.50 g, 2.36 mmol) in CH₂Cl₂ (5 mL) were added 1.5 mL of AcCl and one drop H₂SO₄. The reaction mixture was stirred for 24 h at room temperature. The solvent and excess of AcCl were evaporated. The residue was dissolved in CHCl₃ and the solution filtered over an basic Al₂O₃ (Aktiv.1; 5 g). Removal of the solvent gave **13a** (0.57 g, 83%). Colorless crystal. Mp 103–104 °C (from hexane–EtOAc). ¹H NMR (200 MHz, CDCl₃) δ 5.90 (dt, 1H, H₅, *J*=10.5, 2.6 Hz), 5.69–5.58 (m, 3H, H₂, H₃ and H₄), 5.22 (dd, 1H, H₁, *J*_{1,6}=8.4 Hz, *J*_{1,2}=2.0 Hz), 4.72 (dm, 1H, H₆, *J*_{1,6}=8.4 Hz), 2.11 (s, 3H), 2.10 (s, 3H), 2.03 (s, 3H). ¹³C NMR (50 MHz, CDCl₃) δ 171.9, 171.5 (2C), 131.5, 128.4, 75.4, 71.1, 69.4, 56.7, 22.6 (3C). IR (KBr) 2969, 1754, 1430, 1373, 1226, 1157, 1075, 1033, 917 cm⁻¹. Anal. calcd for C₁₂H₁₅ClO₆ (290.70): C, 49.58; H, 5.20; Found: C, 49.38, H, 5.16.

4.1.7. (1 α ,2 α ,3 α ,6 β)-6-Chloro-4-cyclohexene-1,2,3-triol (13b). A stirred solution of **13a** (0.35 g, 1.20 mmol) in 20 mL of methanol was cooled to 0 °C. At the given

temperature HCl gas was passed through the solution over 20 min. The reaction flask was closed with a stopper and stirred at room temperature for 1 h. Removal of the solvent, methyl acetate and HCl under reduced pressure (30 °C, 25 mm Hg) and recrystallization from EtOAc gave chloroconduiritol **13b** (0.16 g, 82%). Colorless crystal. Mp 128–130 °C (from EtOAc). ¹H NMR (200 MHz, DMSO-*d*₆) δ 5.63–5.49 (AB system, 2H, H₄ and H₅, *J*_{4,5}=10.5 Hz), 4.54 (br d, 1H, H₆, *J*_{1,6}=7.4 Hz), 4.16–3.96 (m, 4H, 3×OH and H₂), 3.82 (br s, 1H, H₃), 3.59 (br d, 1H, H₁, *J*=7.4 Hz). ¹³C NMR (200 MHz, DMSO-*d*₆) δ 133.5, 128.5, 76.4, 74.4, 69.3, 63.6. IR (film) 3326, 2929, 2894, 1428, 1351, 1312, 1258, 1150, 1027, 927, 888, 850 cm⁻¹. Anal. calcd for C₆H₉ClO₃ (164.59): C, 43.78; H, 5.51; Found: C, 43.58, H, 5.53.

4.1.8. (2*exo*,3*exo*,5*endo*,6*exo*)-5,6-Dibromo-7-oxa-bicyclo[2.2.1] heptan-2,3-diol diacetate (12). To a solution of *exo*-diacetate **4** (0.25 g, 1.18 mmol) in CH₂Cl₂ (5 mL) were added 1 mL of AcBr and one drop H₂SO₄. The reaction mixture was stirred for 12 h at room temperature. The solvent and excess of AcBr were evaporated. The residue was dissolved in CHCl₃ and the solution filtered over an basic Al₂O₃ (Aktiv.1; 5 g). Removal of the solvent gave dibromide **12** (0.34 g, 77%). Colorless crystal. Mp 99–101 °C (from hexane–EtOAc). ¹H NMR (200 MHz, CDCl₃) δ 5.65 (d, 1H, H₃, *J*_{2,3}=6.2 Hz), 5.06 (d, 1H, H₂, *J*_{2,3}=6.2 Hz), 4.64 (br d, 1H, H₄, *J*_{4,5}=5.4 Hz), 4.54 (br s, 1H, H₁), 4.24 (dd, 1H, H₅, *J*_{4,5}=5.4 Hz, *J*_{5,6}=3.4 Hz), 3.95 (d, 1H, H₆, *J*_{5,6}=3.4 Hz), 2.11 (s, 3H), 2.08 (s, 3H). ¹³C NMR (50 MHz, CDCl₃) δ 171.7, 171.5, 90.3, 85.2, 74.9, 74.7, 51.8, 51.5, 22.3 (2C). IR (KBr) 3018, 1757, 1433, 1379, 1248, 1086, 1067, 1020, 916. Anal. calcd for C₁₀H₁₂Br₂O₅ (372.01): C, 32.29; H, 3.25; Found: C, 32.16, H, 3.23.

4.1.9. Preparation of 2b from endo-diacetate 1. To a solution of *endo*-diacetate **1** (1.00 g, 4.72 mmol) in CH₂Cl₂ (50 mL) were added 3 mL of AcBr and one drop H₂SO₄. The reaction mixture was stirred for 5 h at room temperature. The solvent and excess of AcBr were evaporated. The residue was dissolved in CHCl₃ and the solution filtered over an basic Al₂O₃ (Aktiv.1; 5 g). Removal of the solvent gave oily **2b**⁴ (1.49 g, 94%).

4.1.10. Preparation of 3b from endo-diacetate 1. To a solution of *endo*-diacetate **1** (1.00 g, 4.72 mmol) in CH₂Cl₂ (50 mL) were added 3 mL of AcCl and one drop H₂SO₄. The reaction mixture was stirred for 12 h at room temperature. The solvent and excess of AcCl were evaporated. The residue was dissolved in CHCl₃ and the solution filtered over a basic Al₂O₃ (Aktiv.1; 5 g). Removal of the solvent gave oily **3b**⁴ (1.07 g, 78%).

4.1.11. Preparation of 2b from epoxide 5. To a solution of epoxide **5** (0.80 g, 4.76 mmol) in 50 mL of CH₂Cl₂ was added a 3 mL of acetyl bromide. The reaction mixture was magnetically stirred at room temperature for 12 h. The solvent and excess of acetyl bromide were evaporated. The residue was dissolved in CHCl₃ and the solution filtered over an basic Al₂O₃ (Aktiv.1; 5 g). Removal of the solvent gave oily **2b**⁴ (1.33 g, 83%).

4.1.12. Preparation of 3b from epoxide 5. The procedure

described in Section 4.1.11 was applied to epoxide **5** using AcCl to give oily **3b**⁴ (85%).

Acknowledgements

We thank Ataturk University for financial support of this project. We thank Professor Dr. Yunus Akcamur and Dr. Mustafa Sacmaci for elemental analysis, and Dr. Hamdullah Kilic for helpful discussions. We also thank Assoc. Professor Dr. H. Inci Gul for providing some of the references.

References and notes

1. Tatsuta, K. In *Carbohydrate mimics: concepts and methods*. Chapleur, Y., Ed.; Wiley-VCH: Weinheim, 1998; pp 283–305.
2. (a) Elbein, A. D. *Methods Enzymol.* **1987**, *138*, 661–709, (Complex Carbohydr., Pt. E). (b) Elbein, A. D. *Annu. Rev. Biochem.* **1987**, *56*, 497–534. (c) Elbein, A. D. *FASEB J.* **1991**, *5*, 3055–3063. (d) Legler, G. *Methods Enzymol.* **1977**, *46*, 368–381. (e) Salvucci, M. E. *Arch. Insect Biochem.* **2000**, *45*, 117–128. (f) Trudel, G. C.; Herscovics, A.; Holland, P. C. *Biochem. Cell Biol.* **1988**, *66*, 1119–1125. (g) Alonso, J. M.; Santa-Cecilia, A.; Calvo, P. *Eur. J. Biochem.* **1993**, *215*, 37–42.
3. (a) Guo, Z. X.; Haines, A. H.; Taylor, R. J. K. *Synlett* **1993**, 607–608. (b) Guo, Z. X.; Haines, A. H.; Pyke, S. M.; Pyke, S. G.; Taylor, R. J. K. *Carbohydr. Res.* **1994**, *264*, 147–153. (c) Haines, A. H.; King, A. S. H.; Knight, J. R.; Nguyen, V. A. *Tetrahedron Lett.* **1998**, *39*, 4393–4396. (d) Hudlicky, T.; Luna, H.; Olivo, H. F.; Andersen, C.; Nugent, T.; Price, J. D. *J. Chem. Soc. Perkin Trans. 1* **1991**, 2907–2917.
4. Baran, A.; Kazaz, C.; Seçen, H.; Sütbeyaz, Y. *Tetrahedron* **2003**, *59*, 3643–3648.
5. (a) Mikhailov, B. M.; Nikolaeva, N. D. *Izv. Akad. Nauk. SSSR, Ser. Khim.* **1963**, 1368–1373, Chem. Abstr. **1963**, *59*, 15296. (b) Polivka, Z.; Feries, M. *Chemické Listy* **1968**, *62*, 869–894, Chem. Abstr. **1969**, *70*, 20114.
6. (a) Smorgonskii, L. M. *Zh. Obshch. Khim.* **1947**, *17*, 416–420. (b) Iqbal, J.; Khan, M. A.; Srivastava, R. R. *Tetrahedron Lett.* **1988**, *29*, 4985–4986. (c) Iqbal, J.; Srivastava, R. R. *Tetrahedron* **1991**, *47*, 3155–3170. (d) Bhar, S.; Ranu, B. C. *J. Org. Chem.* **1995**, *60*, 745–747.
7. Jung, P. M. J.; Motherwell, W. B.; Williams, A. S. *Chem. Commun.* **1997**, 1283–1284, We thank Professor W. B. Motherwell for providing unpublished NMR data of (1 α ,2 α ,3 α ,6 β)-6-bromo-4-cyclohexene-1,2,3-triol triacetate.
8. (a) Dastan, A.; Demir, U.; Balci, M. *J. Org. Chem.* **1994**, *59*, 6534–6538. (b) Senocak, E.; Taskesenligil, Y.; Tumer, F. *Turk. J. Chem.* **2002**, *26*, 939–945.
9. (a) Carless, H. A. J. *Tetrahedron Lett.* **1992**, *33*, 6379–6382. (b) Ramesh, K.; Wolfe, M. S.; Lee, Y.; Velde, D. V.; Borchardt, R. T. *J. Org. Chem.* **1992**, *57*, 5861–5868. (c) Seçen, H.; Gültekin, S.; Sütbeyaz, Y.; Balci, M. *Synth. Commun.* **1994**, *24*, 2103–2108. (d) Hudlicky, T.; Thorpe, A. J. *Synlett* **1994**, 899–901. (e) Hudlicky, T.; Abboud, K. A.; Entwistle, D. A.; Fan, R.; Maurya, R.; Thorpe, A. J.; Bolonick, J.; Myers, B. *Synthesis* **1996**, 897–911. (f) Banwell, M. G.; Haddad, N.; Hudlicky, T.; Nugent, T. C.; Mackay, M. F.; Richards, S. L. *J. Chem. Soc., Perkin Trans. 1* **1997**, 1779–1791. (g) Jarvest, R. L.; Berge, J. M.; Houge-Frydrych, C. S. V.; Mensah, L. M.; O'Hanlon, P. J.; Pope, A. J. *Bioorg. Med. Chem. Lett.* **2001**, 2499–2502.
10. Hudlicky, T.; Tian, X.; Königsberger, K.; Rouden, J. J. *Org. Chem.* **1994**, *59*, 4037–4039.
11. Yang, N. C.; Chen, M. J.; Chen, P. *J. Am. Chem. Soc.* **1984**, *106*, 7310–7315.